BioCryst Pharmaceuticals
Clinical trials sponsored by BioCryst Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing oral therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug trial hopes to tame rare skin disease Results expected Oct 2026 (estimated)
-
Eye injection study for diabetes-related vision loss ends early
Disease control Stopped earlyThis study tested a single injection of avoralstat into the eye for people with diabetic macular edema, a condition that causes vision loss in diabetes. Only 3 adults took part before the study was stopped early. The main goal was to check safety and see if the drug might help re…
Phase 1 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
BCX9930 safety checked in PNH patients who benefited from treatment
Disease control Stopped earlyThis study looked at the long-term safety of BCX9930, an oral medication, for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants and aimed to monitor side effects. The study was terminated…
Phase 2 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC